On May 29th, Gelunhui reported that an investor asked Valiant Co., Ltd. (002643.SZ) on the investor interaction platform, "Do pharmaceutical companies, such as Semaglutide, lay out in the field of diabetes weight loss drugs?" The company replied that Vildagliptin tablets produced by its subsidiary, Yantai Valiant Pharmaceutical Co., Ltd., are suitable for treating type 2 diabetes.
万润股份(002643.SZ)：子公司产品维格列汀片适用于治疗2型糖尿病
Wanrun Co., Ltd. (002643.SZ): The subsidiary product vildagliptin tablets are suitable for treating type 2 diabetes
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.